Valneva SE
Specialty vaccine company developing and commercializing vaccines for infectious diseases.
VLA | PA
Overview
Corporate Details
- ISIN(s):
- AT0000A10B99 (+3 more)
- LEI:
- 969500DIVIP5VKNW4948
- Country:
- France
- Address:
- 6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
- Website:
- https://valneva.com/
- Sector:
- Manufacturing
Description
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2026-01-08 18:30 |
Valneva SE - Declaration of voting rights - December 2025
|
English | PDF • 201.8 KB | ||
| 2026-01-08 18:30 |
Déclaration d'actions et de droits de vote de la société Valneva SE - décembre …
|
French | PDF • 194.1 KB | ||
| 2025-12-31 17:45 |
Valneva et le Serum Institute of India annoncent la fin de leur accord de licen…
|
French | PDF • 253.6 KB | ||
| 2025-12-31 17:45 |
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Va…
|
English | PDF • 222.6 KB | ||
| 2025-12-10 17:45 |
Valneva annonce des résultats finaux de Phase 2 positifs sur la persistance des…
|
French | PDF • 255.0 KB | ||
| 2025-12-10 17:45 |
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results …
|
English | PDF • 247.1 KB | ||
| 2025-12-05 18:34 |
VALNEVA Déclaration d’actions et de droits de vote : 30 novembre 2025
|
French | PDF • 188.7 KB | ||
| 2025-12-05 18:34 |
VALNEVA Declaration of shares and voting rights: November 30, 2025
|
English | PDF • 197.2 KB | ||
| 2025-11-26 17:30 |
Valneva va consolider ses activités en France
|
French | PDF • 172.0 KB | ||
| 2025-11-26 17:30 |
Valneva to Further Consolidate its Operations in France
|
English | PDF • 177.2 KB | ||
| 2025-11-26 07:00 |
Valneva annonce des résultats finaux positifs de Phase 2 pour son candidat vacc…
|
French | PDF • 191.3 KB | ||
| 2025-11-26 07:00 |
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candi…
|
English | PDF • 199.6 KB | ||
| 2025-11-20 07:00 |
Valneva publie ses résultats financiers des neuf premiers mois de 2025 et fait …
|
French | PDF • 300.0 KB | ||
| 2025-11-20 07:00 |
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
|
English | PDF • 308.5 KB | ||
| 2025-11-05 18:00 |
VALNEVA Déclaration d’actions et de droits de vote : 31 octobre 2025
|
French | PDF • 200.0 KB |
Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valneva SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valneva SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-03-18 | N/A | Other | Buy | 44,222 | N/A |
| 2024-01-03 | N/A | Other | Other | 34,802 | N/A |
| 2023-06-20 | N/A | Other | Sell | 192,547 | 1,406,228.50 EUR |
| 2023-06-19 | N/A | Other | Sell | 30,661 | 209,629.26 EUR |
| 2023-06-16 | N/A | Other | Sell | 85,589 | 582,493.06 EUR |
| 2023-06-15 | N/A | Other | Sell | 28,179 | 189,503.78 EUR |
| 2023-06-14 | N/A | Other | Sell | 228,951 | 1,519,914.11 EUR |
| 2023-06-13 | N/A | Other | Sell | 29,401 | 187,922.37 EUR |
| 2023-06-12 | N/A | Other | Sell | 117,854 | 733,782.57 EUR |
| 2023-05-10 | N/A | Other | Buy | 87,523 | N/A |
Peer Companies
